SCHEMBL2860713

SCHEMBL2860713

OC1CSCC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8420119 1.00
SCHEMBL10629749 1.00
SCHEMBL18266878 1.00
SCHEMBL3367148 1.00
SCHEMBL5119518 0.84
SCHEMBL11769202 0.78
SCHEMBL303459 0.76
SCHEMBL11078940 0.75
SCHEMBL1065685 0.75
SCHEMBL8256581 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3833668-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-19 EP claimed
WO-2024029877-A1 NOVEL PURINE DERIVATIVE COMPOUNDS AS A3 ADENOSINE RECEPTOR AGONISTS 주식회사 넥스트젠바이오사이언스 2024-02-08 WO claimed
EP-2219260-B1 ELECTROLYTIC COMPOSITION AND PHOTOELECTRIC CONVERSION ELEMENT USING THE SAME FUJIKURA LTD (JP) 2015-11-04 EP claimed
EP-2142549-A1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT FM Therapeutics Co., Ltd. (KR) 2010-01-13 EP claimed
WO-2008108508-A1 ADENOSINE DERIVATIVES, METHOD FOR THE SYNTHESIS THEREOF, AND THE PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE INFLAMMATORY DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT FM THERAPEUTICS CO., LTD. (KR) 2008-09-12 WO claimed
EP-0885940-B1 Ink jet inks comprising anti-curl agents and printing processes XEROX CORP (US) 2008-02-20 EP claimed
US-5997623-A Ink jet inks comprising anti-curl agents and printing processes XEROX CORPORATION (US) 1999-12-07 US claimed
EP-0885940-A1 Ink jet inks comprising anti-curl agents and printing processes XEROX CORPORATION (US) 1998-12-23 EP claimed
US-4288433-A THIOETHER AND A XANTHINE DERIVATIVE L'OREAL (FR) 1981-09-08 US claimed
US-3950532-A ANTIDANDRUFF L'OREAL (FR) 1976-04-13 US claimed
JP-62169777-A None JP disclosed
US-11993602-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-05-28 US disclosed
WO-2024029877-A1 NOVEL PURINE DERIVATIVE COMPOUNDS AS A3 ADENOSINE RECEPTOR AGONISTS 주식회사 넥스트젠바이오사이언스 2024-02-08 WO disclosed
EP-4234021-A2 PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOSINE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF DIABETIC NEPHROPATHY Future Medicine Co., Ltd. (KR) 2023-08-30 EP disclosed
CN-116350649-A Pharmaceutical composition for preventing and/or treating cholangitis or liver diseases caused by cholangitis 未来制药有限公司 2023-06-30 CN disclosed
US-4080465-A Topical application of cis or trans 3,4-thiolannediol to reduce or substantially eliminate the greasy appearance of the skin SOCIETE ANONYME DITE: L'OREAL (FR) 1978-03-21 US disclosed
US-4080465-A Topical application of cis or trans 3,4-thiolannediol to reduce or substantially eliminate the greasy appearance of the skin SOCIETE ANONYME DITE: L'OREAL (FR) 1978-03-21 US disclosed
US-3950532-A ANTIDANDRUFF L'OREAL (FR) 1976-04-13 US disclosed
US-3950532-A ANTIDANDRUFF L'OREAL (FR) 1976-04-13 US disclosed
US-3950532-A ANTIDANDRUFF L'OREAL (FR) 1976-04-13 US disclosed